https://app.borsa321.com/news/2026/10/24/amgen-reports-imdelltra-plus-durvalumab-extends-median-overall-survival-to-21-1-months 2026-10-24T14:42:29.051Z https://app.borsa321.com/news/2026/10/24/amgen-reports-improved-survival-rates-for-imdelltra-imfinzi-combination-in-small-cell-lung-cance 2026-10-24T14:41:22.742Z